Finance & Capital Markets

1. Public Sector Forged, Private Sector Tested With Renovaro BioSciences' Mark Dybul, M.D. 12/6/2023

   During his leadership of the President's Emergency Plan for AIDS Relief during the George W. Bush administration, Dr. Mark Dybul, M.D. shepherded programs credited with saving more than 25 million lives. For many years after that public service drew to a close, he continued the mission as executive director of The Global Fund to Fight AIDS, Tuberculosis, and Malaria--working in lockstep with not only the world's leading scientists, but the likes of Bono and Sir Elton John along the way. 

2. Clinical Leadership with Cue Biopharma's Anish Suri, Ph.D. & Dan Passeri, J.D. 10/20/2023

   On a road trip to Boston, the Business of Biotech caught up with podcast alum Dan Passeri, J.D., CEO at Cue Biopharma, and enjoyed a two-for-one with CSO and President Anish Suri, Ph.D. at Cue's headquarters just feet below the Auerbach Center. Among other things, we discussed the duo's complementary leadership approach as the company takes multiple candidates into the clinic, why Passeri leans into his biotech legal background almost every day he's at work, why Cue's discretely targeted IL-2 approach eliminates the absurdity of early IL-2 failures, and a whole lot more.

3. The Innovator's Dilemma with Lumen Bioscience's Brian Finrow, J.D. 3/4/2024

   In biotech, when "one of these things doesn't look like the other one," it can be a blessing or a curse. On one hand, scientific novelty is praised and rewarded. On the other, unfamiliarity breeds skepticism from the investment community. Brian Finrow, J.D. embraces that reality and the challenges that come with it.

4. Picking Biotech Jockeys With SR One's Simeon George, M.D. 9/15/2024

   SR One Capital Management CEO Simeon George, M.D. has a seemingly innate ability to pick winning biotech builders. On the Business of Biotech, Dr. George shares insight into the decision-making processes that have contributed to his success at picking winners as an investment banker and biotech venture capitalist. Listen now!

5. Biotech Cash Management With Allan Shaw 8/2/2023

   It’s been said that clinical trials are where emerging biotechs go to die. If the science doesn't kill quickly, poor cash management will slowly. On this week's episode of the Business of Biotech, our favored biotech finance management maven, Allan Shaw, offers pointed advice on stretching cash runways for the long run.

6. How To Be A CFO With Insmed's Sara Bonstein 4/9/2025

   On today's episode of the Business of Biotech, we're speaking with Sara Bonstein, Chief Financial Officer at Insmed, about what it takes to be a successful CFO. Sara provides useful insights on how to lead teams, especially when those teams have deeper subject matter expertise.

7. The Year's Top Stories With Allan Shaw 12/26/2021

   Join your host Matt Pillar and guest Allan Shaw for a no-holds-barred retrospective on the year's top stories and trends. From the frontlines of the COVID-19 pandemic to the questionable approval of Aduhelm to leadership instability at the FDA and more, Shaw dissects the year past and predicts how those stories will influence the biotech industry in 2022 and beyond.

8. Funding Tips And Moving From R&D To Commercial With Madrigal Pharmaceuticals' Mardi Dier 11/5/2025

   On this week's episode of the Business of Biotech, Mardi Dier, CFO at Madrigal Pharmaceuticals, talks about building relationships in investment banking and investor relations before moving into business development and becoming a chief financial officer. 

9. BoB@JPM: Peter Anastasiou, Capsida Biotherapeutics 2/9/2025

   From the JP Morgan Healthcare Conference in San Francisco, Peter Anastasiou, CEO of Capsida Biotherapeutics, discusses his journey from big pharma to biotech and the challenges he faces on the leading edge of first-generation gene therapies.

10. Athersys' Ivor Macleod On Bringing Big-League Financial Experience To An Emerging Biotech 8/13/2020

    The Business Of Biotech "Summer Executive Sessions" kick off with a candid conversation with Athersys CFO Ivor Macleod, who brings years of finance leadership at Roche, Merck, and other big pharmas to Athersys as the company readies its lead candidate for life beyond clinical trials. Join us for a discussion on how Macleod is applying big-league finance principles to an emerging biopharma company, and what he's learned about managing funds in a pre-commercial biotech environment.